Every year, advances are made in treating patients with a variety of blood cancers as well as benign hematologic diseases. The physicians and scientists in the Division of Hematologic Oncology, part of MSK’s Department of Medicine, are key players in advancing translational and clinical research as well as establishing the standard of care for these patients. Our Annual Reports reflect the exciting accomplishments and progress being made.